Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour. Some approaches have already reached the clinical trial stage, with others not far behind. 2 After activation by an antigen presenting cell, a T helper cell segregates the cytokines.
98 
Let's personalize your content